Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 36,460 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 36,460 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $756,298.62. This trade represents a 56.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44.

Hims & Hers Health Stock Up 6.7 %

Shares of NYSE HIMS opened at $29.71 on Wednesday. Hims & Hers Health, Inc. has a 12 month low of $8.44 and a 12 month high of $35.02. The company has a market cap of $6.49 billion, a price-to-earnings ratio of 67.51 and a beta of 1.31. The business has a fifty day simple moving average of $27.74 and a 200-day simple moving average of $21.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period last year, the company posted ($0.04) earnings per share. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in HIMS. Victory Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after buying an additional 1,212 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Hims & Hers Health by 1,391.3% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 149,176 shares of the company’s stock worth $3,012,000 after acquiring an additional 139,173 shares during the period. Amalgamated Bank grew its stake in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Hims & Hers Health by 140.7% in the second quarter. Hsbc Holdings PLC now owns 138,224 shares of the company’s stock worth $2,727,000 after purchasing an additional 80,810 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Hims & Hers Health during the second quarter worth approximately $808,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HIMS. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Finally, Needham & Company LLC increased their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.